NORTHVALE, N.J., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company")
(OTCBB:ELTP), announced results for the quarter ended December 31, 2016, the third quarter of its 2017 fiscal year.
Consolidated revenues for the third quarter of Fiscal 2017 were $2.3 million, a 6% increase on a year-on-year
basis. Continued growth of Elite’s niche generic product lines drove the revenue increase. In addition, Elite’s product development
activities continued, with $1.5 million being spent on the development of Elite’s pipeline of products during the quarter.
“This was an important quarter for Elite’s pipeline,” commented Nasrat Hakim, President and CEO of Elite. “We had a
positive meeting with the FDA on SequestOx™ that provides Elite a path to resubmission of the NDA. We followed the filing of
a Percocet generic the previous quarter with a filing of a Norco generic this quarter. We have made tremendous progress on
the SunGen co-development products and are on track to file two of these products in about 12 months from now. We also had a
solid quarter for our financials.”
About Elite’s Abuse Deterrent
Technology
Elite’s proprietary abuse deterrent technology, ART™, is a multi-particulate capsule which contains an opioid agonist in addition
to naltrexone, an opioid antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product
is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases as intended
providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed or dissolved, the
opioid antagonist is designed to release and so block the effects of active opioid agonist. The absorption of the naltrexone is
intended to block the euphoria by preferentially binding to the same receptors in the brain as the opioid agonist and thereby
reducing the incentive for abuse or misuse by recreational drug abusers. Elite’s pharmacological approach to abuse-deterrence can
be applied to a wide range of opioids used today in pain management.
Conference Call
Information
Elite's management will host a conference call to discuss the results of operations and provide an update on recent business
developments. Company executives will conduct a question and answer session following their remarks.
The financial statements can be viewed in Elite’s Third Quarter Report on Form 10-Q here.
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company which is developing a pipeline of proprietary pharmacological
abuse-deterrent opioid products as well as niche generic products. Elite specializes in oral sustained and controlled release
drug products which have high barriers to entry. Elite owns generic and OTC products which have been licensed to TAGI Pharma,
Epic Pharma and Valeant Pharmaceuticals International. Elite currently has eight commercial products being sold, additional
approved products pending manufacturing site transfer and the NDA for SequestOx™, for which it received the CRL from the FDA.
Elite’s lead pipeline products include abuse-deterrent opioids which utilize the Company’s patented proprietary technology and a
once-daily opioid. These products include sustained release oral formulations of opioids for the treatment of chronic pain.
These formulations are intended to address two major limitations of existing oral opioids: the provision of consistent relief of
baseline pain levels and deterrence of potential opioid abuse. Elite also provides contract manufacturing for Ascend
Laboratories (a subsidiary of Alkem Laboratories Ltd.). Elite operates a GMP and DEA registered facility for research, development,
and manufacturing located in Northvale, NJ. Learn more at www.elitepharma.com.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Including those related to the effects, if any, on future results, performance or other expectations that may
have some correlation to the subject matter of this press release, readers are cautioned that such forward-looking statements
involve risks and uncertainties including, without limitation, Elite’s ability to obtain FDA approval of the transfers of the ANDAs
or the timing of such approval process, delays, uncertainties, inability to obtain necessary ingredients and other factors not
under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from
the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking
statements may include statements regarding the expected timing of approval, if at all, of SequestOx™ by the FDA, the steps Elite
may take as a result of the CRL, and the actions the FDA require of Elite in order to obtain approval of the NDA. These
forward-looking statements are not guarantees of future action or performance. These risks and other factors, including, without
limitation, Elite’s ability to obtain sufficient funding under the LPC Agreement or from other sources, the timing or results of
pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory
authorities and intellectual property protections and defenses, are discussed in Elite's filings with the Securities and Exchange
Commission, including its reports on forms 10-K, 10-Q and 8-K. Elite is under no obligation to update or alter its forward-looking
statements, whether as a result of new information, future events or otherwise.
Contact: For Elite Pharmaceuticals, Inc. Dianne Will, Investor Relations, 518-398-6222 Dianne@elitepharma.com www.elitepharma.com
